Head-to-head · WeighScore
Collective vs Invigor Medical
By GLP-1 ScorecardUpdated
Score comparison
Invigor Medical has the higher recorded score — 86.1/100 to 71.6/100.
Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Now Try Invigor, this platform advertises class-based GLP-1 plans; confirm your medicine and supply before accepting its starting price.
Before you choose
Before comparing the headline prices, the Collective review and the Invigor Medical review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Collective vs Ondra Health and Contour Health vs Invigor Medical compare each of them with another graded program, and the list of alternatives to Collective ranks the programs closest to Collective on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Collective | Invigor Medical |
|---|---|---|
| WeighScore | 71.6/100 | 86.1/100 |
| Grade | C | B |
| Site position | #66 | #9 |
| Semaglutide | $59/mo (plus a required $199/year membership that renews annually) | Medication-specific quote unconfirmed; public GLP-1 treatment starts at $225. |
| Tirzepatide | $69/mo (plus a required $199/year membership that renews annually) | Medication-specific quote unconfirmed; public GLP-1 + GIP treatment starts at $350/month. |
| Coverage | 44 states; excludes AL, CA, LA, MA, MS and WA | U.S. only; confirm medication-specific state availability |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #66 · C
Strengths
- Publishes flat medication prices across doses
- Membership includes doctor messaging, ongoing check-ins and nutrition support
- Express cold shipping is included
- A 21-day membership trial is available; medication remains payable
- Publishes the six states it does not currently serve
What to consider
- The $199 annual membership is additional to medication
- Membership renews automatically each year; fees generally are not refundable, including unused portions
- Terms permit a prescription-transmission technology fee without pricing it
- The reviewed public pages do not name the dispensing pharmacy
- The reviewed pricing does not define a medication month as a calendar month or a four-week cycle
Strengths
- Consultation, medication and supplies advertised together
- Ordinary and microdose treatment listings are separately presented
- Clinical policy describes virtual consultation and relevant testing when needed
What to consider
- Current medication-specific dose and supply quote is unconfirmed
- Cancel new orders before the prescription enters the practitioner's queue
- Subscriptions need seven days’ notice before renewal processing; charges may occur early
- No universal GLP-1 lab panel, frequency or separate testing price published
Featured provider
Collective
Collective scores 71.6/100 (C). Collective pairs $59 semaglutide and $69 tirzepatide with a required $199 annual membership, with care messaging and cold shipping included.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.